Indimitecan - Gibson Oncology
Alternative Names: LMP-776; NSC-725776Latest Information Update: 28 Feb 2025
At a glance
- Originator National Cancer Institute (USA); Purdue University
- Developer National Cancer Institute (USA)
- Class Antineoplastics; Imidazoles; Isoquinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Lymphoma; Solid tumours
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
- 24 Feb 2022 Indimitecan - Gibson Oncology is available for licensing as of 24 Feb 2022. https://gibsononcology.com/our-pipeline/
- 17 Jan 2022 Indimitecan is still in phase I trials for Solid tumours in USA (Gibson Oncology pipeline, January 2022)